News Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse Staff September 11, 2023 Iframe sync Post navigation Previous: APRINOIA Therapeutics Announces Strategic Investment From The Alzheimer’s Drug Discovery Foundation (ADDF)Next: Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer More Stories Clinical Trial Diagnostics Healthcare News Pharmaceutical CelLBxHealth PLC Announces Board Changes Staff January 12, 2026 Healthcare News Pharmaceutical Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms Staff January 12, 2026 Diagnostics EHR Healthcare News Pharmaceutical Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope Staff January 11, 2026
